*Refresh the page if the below document does not appear.
Piramal Pharma lists at ₹200 but fell 5% to end up at ₹190
Nandini Piramal mentioned that the listing of the demerged entity on BSE (Bombay Stock Exchange) and the NSE (National Stock Exchange) is sort of “return to the roots” . The company debuted at ₹201.80 on the BSE, and ₹200 on the NSE.
Indegene acquires US-based firm CultHealth, marketing agency for life sciences brands
The acquisition done by the subsidiary of Bengaluru-based firm Indegene Private Limited, will supplement its commercialization portfolio including drug discovery and development to marketing and sales, adding brand strategy and market development capabilities with patient engagement platforms.
CDSCO finds 59 NSQ drug samples in the month of Septmeber 2022
The CDSCO (Central Drugs Standard Control Organization) has declared 59 drug samples out of 1456 drug samples as NSQ (Not of Standard Quality) but none of them were found to be misbranded or spurious in September 2022.
J&J signals lay-offs amidst consumer health separation and inflation pressure
During the third quarter’s earning call on Tuesday, CFO (Chief Financial officer) of Johnson & Johnson group mentioned that the company is looking for an opportunity to “rightsize their infrastructure”. He added that the macroeconomic pressure that all the companies are facing is something that even they will have to address.
Genome Valley life sciences cluster to get ₹1,100 crore investments
The Life Sciences cluster of Genome valley in Hyderabad is going to receive ₹1,100 crore in additional investments and will be able to generate 3,000 new jobs. Telangana industries minister inaugurated around half a dozen of new projects, including a biopharma incubator called B-Hub on the lines of T-Hub.
Forced to switch to single-dose regime due to Cholera Vaccine shortage: WHO
World Health Organization addressed that there is a strained global supply of cholera vaccines which has caused them to instruct the International Coordinating Group (ICG) to temporarily hault the two-dose regimen of the vaccine and switch to single-dose.
Merck faces formal investigation in France over thyroid drug
On Wednesday, the company was booked over
issuing possibly misleading information
regarding its Thyroid drug product Levothyrox.
The lawyer for Merck, Mario-Pierre Stasi said that
the company will co-operate with the authorities
for all the proceedings and the case will be
allowed to run its full course.
